ArticleInternational journal of clinical and experimental pathology2017
MiR-181d functions as a potential tumor suppressor in oral squamous cell carcinoma by targeting K-ras.
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 7 citations in OpenAlex.
- Roles of miR-181 Family Members in OSCC: Implications for Therapy and Diagnostics.Cancer medicine · 2025Review
- A MiR181/Sirtuin1 regulatory circuit modulates drug response in biliary cancers.Clinical and experimental medicine · 2024Article
- The lncRNA MIAT/miR-181a-5p axis regulates osteopontin (OPN)-mediated proliferation and apoptosis of human chondrocytes in osteoarthritis.Journal of molecular histology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral squamous cell carcinoma (OSCC) is one of the most frequent carcinomas all over the world, and the mechanism of its progression remains poorly understood. MicroRNAs have been found to play pivotal roles in many cancers including OSCC. However, the detailed roles of miRNAs in OSCC remain to be fully elucidated. In this study, we aimed to investigate the role of miR-181d in the progression of OSCC and to further elucidate its possible regulatory mechanism. Differentially expressed miRNAs between OSCC tissues and adjacent normal tissues were identified by microarray and validated using quantitative reverse transcription PCR (qRT-PCR). Moreover, the effects of miR-181d on the cell viability and apoptosis were investigated. In addition, a direct target of miR-181a, K-ras was assessed by the luciferase reporter assay and western blot. K-ras was overexpressed to evaluate its reverse effect on miR-181d mediated tumor suppression in OSCC. A panel of 54 differentially expressed miRNAs was identified by microRNA array. Among them, miR-181d was showed to be significantly downregulated. We also found that miR-181d lowly expressed in 20 pairs of OSCC tissues and four cell lines compared with that in adjacent normal tissues and human normal oral keratinocyte cells. In vitro assays showed that upregulation of miR-181d markedly decreased cell viability and increased OSCC cell apoptosis. Furthermore, we demonstrated that K-ras was a target of miR-181d and there was a negative correlation between miR-181d and K-ras expression in OSCC tissues. Importantly, overexpression of K-ras reversed the inhibitory effects of miR-181d mimics on OSCC cells. miR-181d functions as an OSCC suppressor by targeting K-ras oncogene. Thus, miR-181d may serve as a novel therapeutic target for treating OSCC.
Indexed as
Identifiers
31966632PMC6965231W3027689744What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.